Addressing the Incremental Benefit of Histamine Dihydrochloride When Added to Interleukin-2 in Treating Acute Myeloid Leukemia: A Bayesian Meta-Analysis

REFERENCES

• American Cancer Society. Cancer facts and figures 2009. http://www.cancer.org/acs/groups/content/@nho/documents/document/500809webpdf.pdf. Accessed July 26, 2010.
   Google Scholar
• Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematol Educ Program 2009;396–405.
   Google Scholar
• Baer MR. Is there a role for maintenance therapy in acute myeloid leukemia? Best Pract Res Clin Haem 2009;22:517–521.
   PubMed Web of Science ®Google Scholar
• Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009;31:2349–2370.
   PubMed Web of Science ®Google Scholar
• Blaise D, Attal M, Reiffers J, Michallet M, Bellanger C, Pico J-L, Stoppa A-M, Payen C, Marit G, Bouabdallah R, Sotto JJ, Rossi J-F, Brandely M, Hercend T, Maraninchi D. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 2000;11:91–98.
   PubMed Web of Science ®Google Scholar
• Kolitz JE, Hars V, DeAngelo DJ, Allen SL, Shea TC, Vij R, Hoke E, Bloomfield CD, Caligiuri MA, George SL, Larson RA. Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients < 60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808. Blood (ASH Annual Meeting Abstracts) 2007;110:157.
   Google Scholar
• Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N, Weiman M, Dusenbery K, Shannon K, Luna-Fineman S, Gerbing RB, Alonzo TA. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2008;111:1044–1053.
   PubMed Web of Science ®Google Scholar
• Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrozek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: cancer and leukemia group B study 9720. J Clin Oncol 2008;26:4934–4939.
   PubMed Web of Science ®Google Scholar
• Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis J-H, Reman O, Turlure P, Contentin N, deRevel T, Rousselot P, Preudhomme C, Bordessoule D, Fenaux P, Terre C, Michallet M, Dombret H, Chevret S, Castaigne S. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28:808–814.
   PubMed Web of Science ®Google Scholar
• Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann W-K, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized Phase III trial. Blood 2006;108:88–96.
   PubMed Web of Science ®Google Scholar
• Berry SM, Reese CS, Larkey PD. Bridging different eras in sports. J Am Stat Assoc 1999;94:661–676.
   Web of Science ®Google Scholar
• Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value in Health 2008;11:956–964.
   PubMed Web of Science ®Google Scholar
• Berry DA. Bayesian clinical trials. Nat Rev Drug Discov 2006;5:27–36.
   PubMed Web of Science ®Google Scholar
• Berry SM, Berry DA, Natarajan K, Lin C-S, Hennekens CH, Belder R. Bayesian survival analysis with nonproportional hazards: metanalysis of pravastatin-aspirin. J Am Stat Assoc 2004;99:36–44.
   Web of Science ®Google Scholar
• Berry SM, Ishak KJ, Luce BR, Berry DA. Bayesian meta-analyses for comparative effectiveness and informing coverage decisions. Med Care 2010;48:S137–S144.
   PubMed Web of Science ®Google Scholar
• Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101:1642–1649.
   PubMed Web of Science ®Google Scholar
• Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ. Indirect comparisons of competing interventions. Health Technol Assess 2005;9(26).
   Google Scholar
• Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysis. BMJ 2003;326:1–5.
   Google Scholar